二甲双胍降低多囊卵巢综合征患者的骨转换标志物:一项事后研究
该研究为一项前瞻性多中心、安慰剂对照随机试验的事后分析,纳入74例非肥胖和44例肥胖的多囊卵巢综合征(PCOS)女性,随机接受二甲双胍或安慰剂治疗3个月。结果显示,二甲双胍组全研究人群及非肥胖和肥胖亚组的I型前胶原氨基端前肽(PINP)和I型胶原羧基端交联端肽(CTX)均显著降低,而安慰剂组无显著变化。结论认为二甲双胍与安慰剂相比与骨转换降低相关,提示绝经前PCOS女性骨重建减慢。
要点
- 二甲双胍治疗3个月后,全研究人群及非肥胖和肥胖PCOS女性的PINP和CTX均显著降低。
- 安慰剂组治疗3个月后PINP和CTX无显著变化。
- 肥胖PCOS女性基线PINP和CTX水平低于非肥胖者。
核心结论
- 二甲双胍治疗与安慰剂相比与骨转换降低相关,表现为骨形成和骨吸收标志物降低,提示绝经前PCOS女性骨重建减慢。
研究设计与样本
- 研究为一项先前开展的前瞻性多中心、安慰剂对照随机试验的事后研究,设置于大学诊所。
- 研究队列包括74例体重指数<27 kg/m2的非肥胖和44例体重指数≥27 kg/m2的肥胖PCOS女性,平均年龄27.6±4.0(标准差)岁。
- 干预为随机接受二甲双胍或安慰剂治疗3个月。
主要发现
- 基线时,全研究人群中二甲双胍组与安慰剂组的PINP和CTX血清水平相似。
- 肥胖女性与非肥胖女性相比,基线PINP和CTX水平较低。
- 二甲双胍治疗3个月后,全研究人群以及非肥胖和肥胖女性的PINP和CTX水平均显著降低,而安慰剂组未观察到显著变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the effects of metformin treatment on bone turnover in women with polycystic ovary syndrome (PCOS), as measured by serum concentrations of bone turnover markers. DESIGN: Post hoc study of a previously conducted prospective multicenter, placebo-controlled, randomized study. SETTING: University clinic. PATIENT(S): The study cohort consisted of 74 non-obese women (body mass index < 27 kg/m2) and 44 obese women (body mass index ≥ 27 kg/m2) diagnosed with PCOS, with a mean age of 27.6 ± 4.0 (SD) years. INTERVENTION(S): Randomization to receive metformin or placebo for 3 months. MAIN OUTCOME MEASURE(S): Serum levels of bone formation marker procollagen type I amino-terminal propeptide (PINP) and bone resorption marker carboxy-terminal cross-linking telopeptide of type I collagen (CTX) at baseline and after metformin/placebo treatment. RESULT(S): Serum levels of PINP and CTX were similar between the metformin and placebo groups at baseline in the whole study population. Obese women, when compared with non-obese, had lower baseline levels of PINP and CTX. Levels of PINP and CTX were significantly reduced in the whole study population, as well as in both non-obese and obese women after 3 months of metformin treatment, whereas no significant changes were observed in the placebo group. CONCLUSION(S): Metformin treatment, when compared with placebo, was associated with reduced bone turnover, as suggested by reductions in markers of bone formation and resorption, leading to slower bone remodeling in premenopausal women with PCOS. CLINICAL TRIAL REGISTRATION NUMBER: NCT00994812.
引用
- Lingaiah S, Morin-Papunen L, Risteli J, et al. Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study. Fertil Steril. 2019. PMID: 31227287. doi:10.1016/j.fertnstert.2019.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。